

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

VOLUNTARY ANNOUNCEMENT
FIRST COMMERCIAL CASE OF IBERIS® RDN SYSTEM IN
SWITZERLAND

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that recently, Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (“**Iberis® RDN system**”) developed by a subsidiary of the Company, Shanghai AngioCare Medical Technology Co., Ltd.* (上海安通醫療科技有限公司) (“**AngioCare**”), completed the market access and the first commercial procedure in Switzerland. The procedure was performed at the University Hospital Basel. There were no reported complications or adverse events. The case was supported jointly by Biosensors International Group, Ltd. (“**Biosensors**”) and Angiocare.

AngioCare and Biosensors entered into a strategic partnership covering various geographical regions including but not limited to the European Union countries, the Asia-Pacific region and the Latin America (LATAM) region, regarding the commercialization of Iberis® RDN system.

As of the date of this announcement, Iberis® RDN system is the only renal denervation (“**RDN**”) product approved globally with both transradial approach (“**TRA**”) and transfemoral approach (“**TFA**”). TRA makes RDN safer, more effective and cheaper. Our ultimate goal is to bring outpatient RDN procedures to patients around the world. AngioCare has obtained CE marking for Iberis® RDN system in 2016 in Europe.

About Biosensors

Biosensors is a company incorporated in Bermuda. Biosensors is a subsidiary and one of the business entities of the cardiovascular and cerebrovascular business division of Bule Sail Medical Co., Ltd. (藍帆醫療股份有限公司), a company listed on the Shenzhen Stock Exchange (Stock Code: 002382). Biosensors has operations worldwide and is headquartered in Singapore. The European headquarters are located in Morges, Switzerland. With the combination of a direct sales network and distributors across the world, Biosensors is dedicated to serving the needs of the healthcare community and is committed to, the support of bona fide medical education, advancing the progress of medical science and improving patient care, through training courses, scientific summits and symposia and related events on a regular basis, both in international forums and at national level. Biosensors also participates in some of the major cardiology congresses throughout the world – doing so in a way that complies with all ethical and legal requirements.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that Iberis® RDN system will be ultimately developed and marketed successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive director

Shanghai, the People's Republic of China, October 23, 2025

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.